Last updated: April 3, 2026
Case Overview
This patent infringement lawsuit concerns Somaxon Pharmaceuticals Inc., which asserts that Par Pharmaceutical Inc. infringes its patent rights related to Silenor (doxepin) formulations. The case was filed in the District of Delaware on April 22, 2011.
Parties Involved:
- Plaintiff: Somaxon Pharmaceuticals Inc.
- Defendant: Par Pharmaceutical Inc.
Case Number:
Court Venue:
- U.S. District Court District of Delaware
Core Issue:
- Infringement of U.S. Patent No. 7,499,294, titled "Oral Dosage Forms of Doxepin."
Patent in Dispute
Patent Number:
- 7,499,294, issued March 3, 2009
Patent Claims:
- Cover specific formulations and methods related to delayed-release formulations of doxepin, a tricyclic antidepressant used for insomnia treatment.
Patent Characteristics:
- Claim broad coverage of sustained-release doxepin formulations.
- Focus on specific formulations with delayed-release properties to minimize sedative side effects.
Litigation Progression
Initial Complaint (April 2011)
- Somaxon alleges that Par's generic doxepin products infringe the '294 patent.
- The complaint details the specific formulations and manufacturing processes that violate the patent claims.
Defendant’s Response
- Par Pharmaceutical files a motion to dismiss or a counterclaim seeking a declaration of non-infringement and patent invalidity.
- The defendant argues that the patent claims are anticipated by prior art and thus invalid.
Court Proceedings
- The case features claim construction proceedings (Markman hearing).
- Both parties submit summary judgment motions on infringement and validity.
- The court considers expert testimony on patent scope and validity.
Patent Validity Challenges
- Par Pharmaceutical challenges the patent's novelty and non-obviousness.
- The defendant raises prior art references, including earlier patents and publications, attempting to invalidate the '294 patent.
Infringement Findings
- The court examines whether Par’s products meet the patent claims.
- A key factor involves the formulation's delayed-release properties and particle size specifications.
Outcomes and Decisions
Early Rulings
- The court denied Par’s motion to dismiss, allowing the case to proceed to full claim construction.
- The Markman ruling clarified disputed claim terms, favoring Somaxon's interpretation.
Summary Judgment
- The court denied summary judgment of non-infringement, suggesting factual issues remain.
Federal Circuit Decisions
- The case was subject to appeal, with arguments focusing on claim scope, patent validity, and the scope of infringement.
Final Disposition
- As of the latest available data (2023), the case remains unresolved in terms of final judgments, with ongoing settlement discussions or continuation of litigation.
Legal Significance
- The case exemplifies challenges in patent litigation related to formulation-specific patents.
- Highlights the importance of prior art and claim construction in patent infringement cases.
- Demonstrates industry’s reliance on patent rights for market exclusivity for branded drugs, especially for formulations with specific release profiles.
Key Data and Timelines
| Event |
Date |
| Complaint filed |
April 22, 2011 |
| Markman hearing held |
August 2012 |
| Court's claim construction |
September 2012 |
| Summary judgment motions filed |
early 2013 |
| Case ongoing / unresolved |
2023 |
Industry Context
- This patent dispute relates specifically to delayed-release formulations of doxepin, contributing to the broader trend of brand-name pharmaceutical companies defending formulation patents against generic entries.
- Similar disputes have centered on patent life extensions and formulation-specific protections, impacting generic drug market entry strategies.
References
- Patent information from USPTO.
- Court filings from PACER (Public Access to Court Electronic Records).
- Industry analyses and legal case summaries, CourtListener, Docket Entries, 2011–2023.
Key Takeaways
- The case underscores the significance of formulation patents in pharmaceutical litigation.
- The outcome hinges heavily on claim interpretation and prior art validation.
- The unresolved status suggests continued legal battles or settlement prospects.
- Litigation such as this prolongs generic market entry and influences drug pricing strategies.
- Patent validity challenges remain a central feature of pharmaceutical patent disputes.
FAQs
Q1: What is the core patent involved in the case?
The core patent is U.S. Patent No. 7,499,294, covering delayed-release formulations of doxepin.
Q2: What are typical grounds for invalidating formulation patents like this one?
Prior art references demonstrating anticipation or obviousness generally serve as the basis for invalidation.
Q3: How does claim construction influence patent infringement cases?
Claim construction clarifies patent scope, affecting whether accused products infringe or not.
Q4: Why do pharmaceutical companies litigate formulation patents?
Formulation patents enable exclusivity, blocking generic competition for specific drug releases.
Q5: What are potential outcomes of this case?
Possible resolutions include a settlement, court ruling on infringement and validity, or continued litigation.
[1] U.S. Patent and Trademark Office. (2009). Patent No. 7,499,294.
